Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (3144)	3/21/2019 10:36:36 AM
From: tuck	Read Replies (1) \| Respond to of 3158

Others suggest a bunch f small deals, noting BIIBI has a better record of value creation from their smaller deals. So I don't follow much in the SMID euro space, except for Minerva (NERV) and Intra-Cellular Therapies (ITCI). If they get a good readout later this year, that could potentially put them in play. There are, of course many more to choose from in the SMID range. It's just even harder to pick ones of any quality. A research note I'm seeing says BIIB has 18 billion for M&A. Cheers, Tuck